# An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

> **NCT06024057** · NA · NOT_YET_RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 3 (estimated)

## Conditions studied

- To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)

## Interventions

- **DRUG:** LX101

## Key facts

- **NCT ID:** NCT06024057
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2028-09-30
- **Final completion:** 2038-09-30
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06024057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06024057, "An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06024057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*